Company intelligence / Profile preview
Ho'ola Therapeutics
Delaware, United Stateshoolatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ho'ola Therapeutics owns two advanced oncology programs acquired from Oncternal Therapeutics: zilovertamab, a monoclonal antibody that reached Phase 3, and ONCT-808, a CAR-T therapy targeting ROR1. While zilovertamab's Phase 3 trial under Oncternal was ended prematurely due to commercial challenges, ONCT-808 had reached clinical testing but was paused following a safety event. Both programs are now positioned for further development under Ho'ola Therapeutics.[1][2][3][4][5][8]
- Therapeutic areas
- OncologyHematology
- Modalities
- Monoclonal antibodyCAR-T cell therapyBiologicCell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ho'ola Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ho'ola Therapeutics.